Lectures

Invited Lectures

  1. Exploring the Protein Plasticity of the Human Farnesyl Pyrophosphate Synthase - Therapeutic Implications
    Department of Chemistry, University of Toronto (Toronto, Ontario, August 20, 2012)
  2. Exploring the Protein Plasticity and Therapeutic Value of Prenyl Synthase Enzymes Protein Plasticity and its Role in Inhibiting Human FPPS - Therapeutic Implications
    Department of Chemistry and Pharmaceutical Sciences, Ludwig-Maximilians-Universität (Munich, Germany April 2012)
  3. Novel Inhibitors of Prenyl Synthase Enzymes as Potential Therapeutics
    12th Eurasia Conference on Chemical Sciences (Corfu, Greece, April 2012)
  4. Novel Active Site Inhibitors of Prenyl Synthase Enzymes as Potential Therapeutics
    Chemistry Department, University of Uppsala (Uppsala, Sweden, February 2012)
  5. New Challenges in Drug Discovery: are Prenyl Synthase Enzymes Good Therapeutics Targets ?
    Department of Chemistry, University of Waterloo (Waterloo, Ontario, May 2011)
  6. Design and Synthesis of Molecular Tools that Modulate Metabolic Pathways
    Department of Biochemistry, McGill University (Montreal, May 2010)
  7. Challenges in Drug Discovery and the Role of Academic Research
    Chemical Biology Workshop; Department of Biochemistry, McGill University (Montreal, May 2009)
  8. Current Therapies and Future Hopes for the Treatment of Hepatitis C
    College of Pharmacy, University of New England (Portland, Maine, November 2008)
  9. Current Therapies and Future Hopes for the Treatment of Hepatitis C
    Department of Chemistry, McGill University (Montreal, December 2008)
  10. Current Therapies and Future Hopes for the Treatment of Hepatitis C
    Ironwood Pharmaceuticals (Cambridge, Massachusetts, December 2008)
  11. Current Therapies and Future Hopes for the Treatment of Hepatitis C
    Department of Pharmaceutical Sciences and Chemistry, Ludwig-Maximilians-Universität (Munich, Germany, April 17, 2008)
  12. Current Therapies and Future Hopes for the Treatment of Hepatitis C
    Chemistry Department, Ottawa-Carleton University (Ottawa; November, 2007)
  13. Current Therapies and Future Hopes for the Treatment of Hepatitis C
    Archibald Macallum Lecture, Biochemistry Department, McGill University (Montreal, November 2007)
  14. Current Therapies and Future Hopes for the Treatment of Hepatitis C
    Brisbane Biological and Organic Chemistry Symposium (Institute for Molecular Biosciences, The University of Queensland, Australia; December 2007)
  15. Current Therapies and Future Hopes for the Treatment of Hepatitis C
    Ottawa-Carleton University (Ottawa; November 2005)
  16. Current Therapies and Future Hopes for the Treatment of Hepatitis C
    GNF Institute, San Diego (USA; April 2005)
  17. The Design and Synthesis of Macrocyclic BILN 2061, a Potent Inhibitor of the Hepatitis C Virus: from the NMR Tube to the Clinic.
    29th National Medicinal Chemistry Symposium (Madison, Wisconsin, USA; June 2004)
  18. The design and Synthesis of BILB 2061, a Potent Inhibitor of the Hepatitis C Virus: from the NMR Tube to the Clinic
    9th Naples Workshop on Bioactive Peptides (Anacapri, Italy; May 2004)
  19. Design and Synthesis of Macrocyclic Inhibitors of Hepatitis C Virus; from the NMR Tube to the Clinic
    Charité Universiatsmedizin, Berlin (Germany; August 2004)
  20. Current Therapies and Future Hopes for the Treatment of Hepatitis C
    Queen’s University, Chemistry Department (March 3, 2004)
  21. Design and Synthesis of Macrocyclic Inhibitors of Hepatitis C Virus; from the NMR Tube to the Clinic
    ETH Zentrum, Zuerich, Switzerland (April 24, 2003)
  22. Design and Synthesis of Macrocyclic Inhibitor of the Hepatitis C Virus: from the NMR Tube to the Clinic
    Frontiers in Chemical & Structural Biology (Montreal, Quebec; April 2003)
  23. Design and Synthesis of Macrocyclic Inhibitors of Hepatitis C Virus; from the NMR Tube to the Clinic
    McGill University, Biochemistry Department (Montreal, Quebec; February 2003)
  24. Design and Synthesis of Macrocyclic Inhibitors of Hepatitis C Virus; from the NMR Tube to the Clinic
    McGill University, Chemistry Department (February 7, 2003)
  25. Novel Macrocyclic Inhibitors of the HCV NS3 Protease as Potential Therapeutic Agents of Hepatitis C Infections
    9th International Symposium on HCV and Related Viruses (San Diego, CA; July 2002)
  26. Solid Phase Synthesis of Peptidomimetic Inhibitors for the Hepatitis C Virus NS3 Protease
    32nd Spring Synthesis Symposium of Ottawa - Carleton Chemistry (Ottawa; May 2002)
  27. Solid Phase Synthesis of Peptidomimetic Inhibitors for the Hepatitis C Virus NS3 Protease
    Cambridge Health Institute Conference on Molecular Diversity and High-Throughput Organic Synthesis (San Diego, CA; February 2002)
  28. Design and Synthesis of Macrocyclic Inhibitors of Hepatitis C Virus; from the NMR Tube to the Clinic
    State University of New York, Stony Brook, Chemistry Department (NY, November 8, 2002)
  29. Macrocyclic Inhibitors of the NS3 Protease as Potential Therapeutic Agents of Hepatitis C Virus Infections
    Dalhousie University, Chemistry Department (October 4, 2002)
  30. Macrocyclic Inhibitors of the NS3 Protease as Potential Therapeutic Agents of Hepatitis C Virus Infections
    Acadia University, Chemistry Department (October 3, 2002)
  31. Peptidomimetics as Antiviral Agents
    Gordon Research Conference on Bioorganic Chemistry, Proctor Academy, Andover, NH, USA (June 2001)
  32. Aromatic Peptide Nucleic Acids: A Paradigm of Nucleic Acids
    84th CSC Conference and Exhibition (Montreal, Quebec; May 2001)
  33. Peptidomimetics as Antiviral Agents
    Simon Fraser University, Chemistry Department (April 2001)
  34. Peptidomimetics as Antiviral Agents
    The University of Western Ontario, Chemistry Department (February 2001)
  35. Peptidomimetics as Antiviral Agents
    Queen’s University, Chemistry Department (March 20, 2001)
  36. Synthesis and Physicochemical Properties of a Novel Class of Peptide Nucleic Acids
    International Chemical Congress 2000 of the Pacific Basin Societies (Honolulu, Hawaii; December 2000)
  37. Solid-Phase Synthesis of Peptidomimetic Inhibitors for the Viral NS3 Protease of Hepatitis C
    Gordon Research Conference on Bioorganic Chemistry, Proctor Academy, Andover, NH, USA (June 23, 2000)
  38. Gene Expression: New Tools in Drug Discovery
    Queen’s University, Department of Chemistry (March 27, 2000)
  39. Gene Expression: New Tools in Drug Discovery
    Guelph University, Department of Chemistry and Biochemistry (December 7, 1999)
  40. Gene Expression: New Tools in Drug Discovery
    McMaster University, Department of Chemistry (December 6, 1999)
  41. Peptides as Biochemical Modulators of Gene Expression
    Boehringer Ingelheim Pharmaceuticals, Inc. Ridgefield, Connecticut (February 9, 1999)
  42. Combinatorial Biosynthesis and its Role in Molecular Diversity
    Phytochemical Society of North America 34th Annual Conference (July 11, 1999)
  43. Molecular Recognition in Biopolymers
    BioChem Pharma, BioChem Therapeutics Inc. (June 23, 1998)
  44. Learning to Control Gene Expression: a New Tool in Drug Development
    University of California at Davis, Chemistry Department (February 5, 1998)
  45. Structural Analysis of the Complex Natural Product Verucopeptin and Investigation of its Biosynthetic Origin by 13C 1D-COSY and 1D-INADEQUATE NMR Experiments
    43rd International Conference on Analytical Sciences & Spectroscopy. McGill University, Montreal, Quebec (August 1997)
  46. Biosynthetic Origin of the Tetrahydropyranyl Side Chain of Verucopeptin
    5th US-Japan Seminar on Biosynthesis of Natural Products. Winthrop, Washington, USA (June 1997)
  47. Combinatorial Biosynthesis and its Role in Molecular Diversity
    Bio-Méga / Boehringer Ingelheim Research Inc. (September 30, 1997)
  48. Oligopeptides and Oligoketides as Biochemical Modulators
    Université du Québec à Montréal, Chemistry Department (March 20, 1996)
  49. Some Aspects of Molecular Recognition: Depsipeptides, Enzymes and Enzyme Mimics
    Bio-Méga / Boehringer Ingelheim Research Inc. (February 12, 1996)
  50. Depsipeptides and Polyketides as Biochemical Modulators
    Brown University, Chemistry Department, Providence, RI (June 15, 1995)
  51. Biosynthesis of the Fungal Metabolite Oudenone
    PACIFICHEM'95 Conference, Honolulu, Hawaii (December 1995)
  52. Biochemical Modulators: Oligoketides and Oligopeptides
    3rd Canadian Workshop in Organic Chemistry, Guelph, Ontario (May 1995)
  53. Genotoxins and Biochemical Modulators from Fungal Metabolites
    Institut Armand-Frappier, Laval, Québec, Canada (December 20, 1994)
  54. Novel Biochemical Modulators from Fungal Metabolites
    Ottawa-Carleton Chemistry Institute, Ottawa (September 27, 1993)
  55. Chemical Education in the Golden Age of Biotechnology
    19th Annual Conference of College Chemistry in Canada, Vanier College (June 5, 1992)
  56. Mechanistic Studies on Sesquiterpene cyclase enzymes using Anomalous Substrates
    McGill University, Chemistry Department (October 18, 1991)
  57. Fungal Metabolites : Isolation, Applications and Biosynthesis
    Merck Sharpe & Dohme Research Laboratories, Rahway, N.J., USA (May 17, 1991)
  58. Microbial Metabolites in Plant Biotechnology
    Wellesley College, Wellesley, Massachusetts, USA (June 27, 1991)
  59. Fungal Metabolites in Forestry and Agriculture
    Université du Québec à Montréal, Department of Chemistry (November 1990)
  60. Antifungal Antibiotics from Pisolithus tinctorius
    The Canadian Pacific Symposium on Plant Biotechnology, University of Saskatchewan, Saskatoon (August 1989)
  61. Popularizing Science
    Montreal College Chemistry Symposium, Dawson College, Montreal, Quebec (June 1986)
  62. The Chemistry of Flowers
    11th Annual Conference of College Chemistry Canada John Abbott College, Sainte Anne de Bellevue, Quebec (June 1984)